142 related articles for article (PubMed ID: 21461200)
1. The use of lithium carbonate to prevent lomustine-induced myelosuppression in dogs: a pilot study.
Abrams-Ogg AC
Can J Vet Res; 2011 Jan; 75(1):73-6. PubMed ID: 21461200
[TBL] [Abstract][Full Text] [Related]
2. Tolerability of metronomic administration of lomustine in dogs with cancer.
Tripp CD; Fidel J; Anderson CL; Patrick M; Pratt C; Sellon R; Bryan JN
J Vet Intern Med; 2011; 25(2):278-84. PubMed ID: 21314727
[TBL] [Abstract][Full Text] [Related]
3. CCNU (lomustine) toxicity in dogs: a retrospective study (2002-07).
Heading KL; Brockley LK; Bennett PF
Aust Vet J; 2011 Apr; 89(4):109-16. PubMed ID: 21418164
[TBL] [Abstract][Full Text] [Related]
4. Overdose of lomustine: report of two cases.
Büyükçelik A; Akbulut H; Yalçin B; Ozdemir F; Içli F
Tumori; 2004; 90(6):628-9. PubMed ID: 15762370
[TBL] [Abstract][Full Text] [Related]
5. Tolerability of lomustine in combination with cyclophosphamide in dogs with lymphoma.
Rassnick KM; Bailey DB; Malone EK; Flory AB; Kiselow MA; Intile JL
J Am Anim Hosp Assoc; 2014; 50(3):167-73. PubMed ID: 24659727
[TBL] [Abstract][Full Text] [Related]
6. Effects of lithium carbonate on carboplatin-induced thrombocytopenia in dogs.
Leclerc A; Abrams-Ogg AC; Kruth SA; Bienzle D
Am J Vet Res; 2010 May; 71(5):555-63. PubMed ID: 20433382
[TBL] [Abstract][Full Text] [Related]
7. Frequency and Severity of Neutropenia Associated with Food and Drug Administration Approved and Compounded Formulations of Lomustine in Dogs with Cancer.
Burton JH; Stanley SD; Knych HK; Rodriguez CO; Skorupski KA; Rebhun RB
J Vet Intern Med; 2016; 30(1):242-6. PubMed ID: 26682700
[TBL] [Abstract][Full Text] [Related]
8. Lomustine (CCNU) for the treatment of resistant lymphoma in dogs.
Moore AS; London CA; Wood CA; Williams LE; Cotter SM; L'Heureux DA; Frimberger AE
J Vet Intern Med; 1999; 13(5):395-8. PubMed ID: 10499719
[TBL] [Abstract][Full Text] [Related]
9. Hematological toxicity and therapeutic efficacy of lomustine in 20 tumor-bearing cats: critical assessment of a practical dosing regimen.
Fan TM; Kitchell BE; Dhaliwal RS; Jones PD; Hintermeister JG; Paria BC
J Am Anim Hosp Assoc; 2002; 38(4):357-63. PubMed ID: 12118689
[TBL] [Abstract][Full Text] [Related]
10. Hemorrhagic diathesis and bone marrow aplasia secondary to lomustine overdose in a dog.
Henker LC; Kemper RT; Bianchi SP; Bandinelli MB; Pavarini SP
Vet Clin Pathol; 2019 Jun; 48(2):255-258. PubMed ID: 31062418
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of dexamethasone as a chemoprotectant for CCNU-induced bone marrow suppression in dogs.
Intile JL; Rassnick KM; Bailey DB; Al-Sarraf R; Chretin JD; Balkman CE; Flory AB; Kiselow MA; Wakshlag JJ
Vet Comp Oncol; 2009 Mar; 7(1):69-77. PubMed ID: 19222832
[TBL] [Abstract][Full Text] [Related]
12. Risk factors associated with the onset of lomustine-induced neutropenia in tumour-bearing dogs.
Treggiari E; Cossu G; Valenti P; Taylor A
Vet Comp Oncol; 2022 Sep; 20(3):577-586. PubMed ID: 35249267
[TBL] [Abstract][Full Text] [Related]
13. Pulse-Administered Toceranib Phosphate Plus Lomustine for Treatment of Unresectable Mast Cell Tumors in Dogs.
Burton JH; Venable RO; Vail DM; Williams LE; Clifford CA; Axiak-Bechtel SM; Avery AC; Thamm DH
J Vet Intern Med; 2015; 29(4):1098-104. PubMed ID: 26119008
[TBL] [Abstract][Full Text] [Related]
14. A phase II study to evaluate the toxicity and efficacy of alternating CCNU and high-dose vinblastine and prednisone (CVP) for treatment of dogs with high-grade, metastatic or nonresectable mast cell tumours.
Rassnick KM; Bailey DB; Russell DS; Flory AB; Kiselow MA; Intile JL; Malone EK; Balkman CE; Barnard SM
Vet Comp Oncol; 2010 Jun; 8(2):138-52. PubMed ID: 20579327
[TBL] [Abstract][Full Text] [Related]
15. Treatment of canine mast cell tumors with CCNU (lomustine).
Rassnick KM; Moore AS; Williams LE; London CA; Kintzer PP; Engler SJ; Cotter SM
J Vet Intern Med; 1999; 13(6):601-5. PubMed ID: 10587263
[TBL] [Abstract][Full Text] [Related]
16. Hepatotoxicity associated with CCNU (lomustine) chemotherapy in dogs.
Kristal O; Rassnick KM; Gliatto JM; Northrup NC; Chretin JD; Morrison-Collister K; Cotter SM; Moore AS
J Vet Intern Med; 2004; 18(1):75-80. PubMed ID: 14765735
[TBL] [Abstract][Full Text] [Related]
17. Carboplatin-induced myelosuppression as related to body weight in dogs.
Coffee C; Roush JK; Higginbotham ML
Vet Comp Oncol; 2020 Dec; 18(4):804-810. PubMed ID: 32452107
[TBL] [Abstract][Full Text] [Related]
18. Lomustine and prednisone as a first-line treatment for dogs with multicentric lymphoma: 17 cases (2004-2005).
Sauerbrey ML; Mullins MN; Bannink EO; Van Dorp TE; Kaneene JB; Obradovich JE
J Am Vet Med Assoc; 2007 Jun; 230(12):1866-9. PubMed ID: 17571992
[TBL] [Abstract][Full Text] [Related]
19. Survival times in dogs with presumptive intracranial gliomas treated with oral lomustine: A comparative retrospective study (2008-2017).
Moirano SJ; Dewey CW; Wright KZ; Cohen PW
Vet Comp Oncol; 2018 Dec; 16(4):459-466. PubMed ID: 29797768
[TBL] [Abstract][Full Text] [Related]
20. Combination toceranib and lomustine shows frequent high grade toxicities when used for treatment of non-resectable or recurrent mast cell tumours in dogs: A European multicentre study.
Bavcar S; de Vos J; Kessler M; de Fornel P; Buracco P; Murphy S; Hirschberger J; Argyle DJ
Vet J; 2017 Jun; 224():1-6. PubMed ID: 28697868
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]